Dallas, Texas 04/02/2014 (FINANCIALSTRENDS) – Walgreen Company (NYSE:WAG) reported its second quarter 2014 operating results earlier last week. The highlight of the earnings call was the increase in sales posted by the firm, in spite of headwinds it faced due to adverse weather conditions which prevailed across major swaths of the country for most part of the reporting quarter and less than expected growth in its generic drug segment.
The earnings report also made it obvious that the firms running feud with its one time partner Express Scripts had coasted the firm a significant dip in prescriptions in the past. Now that the issue has been sorted, the firm is hoping to regain lost business from Express Scripts. In spite of these challenges, the firm reported 5.2 percent increase in its quarter earnings in comparison to 2Q13. This was accomplished on the back of the drug store chain managing to grow its same stores sales up by close to 4.3 percent in the 4Q. Correspondingly, its prescription sales saw an improvement of close to 5.8 percent, while its counter sales went up by 2 percent, all in relation to 2Q13 compares.
The firm also plans to shut down a few underperforming stores, while planning to open additional 55 to 75 new stores during the current fiscal. It reported filling out 214 million prescriptions for the quarter, while its outreach program to gain repeat customers gathered steam. It reported 100 million new enrolments in 2Q under this loyalty program.
Walgreen Company (NYSE:WAG) President and CEO Greg Wasson has been quoted to have explained 2Q performance numbers by explaining that, “ sales were $19.6 billion, up 5.1% from $18.6 billion a year ago, driven in part by 4.3% increase in comp store sales. GAAP operating income for the quarter was $1.3 billion, up 4.9% from $1.2 billion last year. Adjusted operating income for the quarter was $1.3 billion, down 4.3% from $1.4 billion in second-quarter 2013”.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.